Multi-laboratory development of bioanalytical methods for two cyclic peptides, cyclorasin9A5 and 3003pep

Area of Science:

• Pharmaceutical Science
• Analytical Chemistry
• Biotechnology

Background:

• Cyclic peptides offer therapeutic advantages like target selectivity and extended half-lives over linear peptides.
• Liquid chromatography-mass spectrometry (LC-MS) is the preferred quantitative bioanalytical technique for complex cyclic peptide structures.
• Challenges in LC-MS bioanalysis of cyclic peptides include precursor ion fragmentation resistance and multiple charge states.

Purpose of the Study:

• To develop and validate LC-MS bioanalytical methods for cyclic peptides (cyclorasin9A5 and 3003pep) across multiple laboratories.
• To assess the impact of inter-laboratory variations in LC-MS systems and sample preparation on method performance.
• To evaluate method compliance with ICH M10 guidelines.

Main Methods:

• Simultaneous development of LC-MS bioanalytical methods in seven different laboratories.
• Application of developed methods under varied sample preparation and LC-MS parameters.
• Validation of methods against ICH M10 acceptance criteria.

Main Results:

• All validation parameters met ICH M10 guidelines, except for carry-over in cyclorasin9A5 analysis.
• Developed LC-MS methods demonstrated comparable performance across diverse laboratory setups after optimization.
• A potential systemic bias was identified in surrogate sample analysis for one peptide, impacting inter-laboratory data comparability.

Conclusions:

• Optimized LC-MS bioanalytical methods for cyclic peptides can achieve consistent performance across different laboratory environments.
• System-specific optimization is necessary for robust cyclic peptide bioanalysis.
• Inter-laboratory data comparison requires careful consideration due to potential systemic biases.